BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis

Diseases of the Colon and Rectum

Volumn 55, Issue 2, 2012, Pages 128-133

  Kalady, Matthew F ^a   DeJulius, Kathryn L ^a   Sanchez, Julian A ^a   Jarrar, Awad ^a   Liu, Xiuli ^a   Manilich, Elena ^a   Skacel, Marek ^b   Church, James M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Dahl Chase Pathology Associates   (United States)

Author keywords

BRAF; Colorectal cancer; Prognosis

Indexed keywords

B RAF KINASE; GENOMIC DNA; BRAF PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CHI SQUARE TEST; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; FROZEN SECTION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HAZARD RATIO; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE; ONCOLOGY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; SEX; TUMOR CELL; WILCOXON SIGNED RANKS TEST; WILD TYPE; ADENOCARCINOMA; ADOLESCENT; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 85047689482     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e31823c08b3     Document Type: Article

References (34)

1. Jass JR. Colorectal cancer: A multipathway disease. Crit Rev Oncog. 2006;12:273-287. (Pubitemid 46524134)
2. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130. (Pubitemid 44953403)
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361: 2449-2460.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J of Med. 1988; 319:525-532.
5. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816-819. (Pubitemid 23167612)
6. Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: Different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 1998;58: 1713-1718. (Pubitemid 28215098)
7. Issa JP. CpG island methylator phenotype in cancer. Nat Rev. 2004;4:988-993.
8. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681-8686. (Pubitemid 29354851)
9. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-793. (Pubitemid 43980599)
10. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum. 2009;52:1039-1045.
11. Ogino S, Meyerhardt JA, Kawasaki T, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007;450:529-537. (Pubitemid 46676250)
12. Sanchez JA, Krumroy L, Plummer S, et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg. 2009;96:1196-1204.
13. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-1206. (Pubitemid 32319494)
14. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257. (Pubitemid 36859476)
15. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol. 2009;2:18.
16. Soulieres D, Greer W, Magliocco AM, et al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti- EGFR therapies. Curr Oncol. 2010;17(suppl 1):S31-S40.
17. Vakiani E, Solit DB. KRAS and BRAF: Drug targets and predictive biomarkers. J Pathol. 2011;223:219-229.
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
19. Preto A, Figueiredo J, Velho S, et al. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol. 2008;214: 320-327. (Pubitemid 351212387)
20. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385-394.
21. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98-99.
22. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-2019.
23. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2011. Available at http://www.nccn.org.
24. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261-1270.
25. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
26. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063-6069.
27. Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer. 2010;102:1762-1768.
28. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009; 101:465-472.
29. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104:856-862.
30. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466-474.
31. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191-195. (Pubitemid 38114179)
32. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-793. (Pubitemid 43980599)
33. Messick CA, Church JM, Liu X, Ting AH, Kalady MF. Stage III colorectal cancer: Molecular disparity between primary cancers and lymph node metastases. Ann Surg Oncol. 2010;17:425-431.
34. Van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003;9:2898-2903. (Pubitemid 36993247)